Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03921242 · ClinicalTrials.gov registry record
Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- 4,888
- Enrollment target
NCT03921242 is a clinical trial that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 4,888 participants.
The verdict
NCT03921242 has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- 4,888 participants
- Enrollment target
Study Summary
This is a proposal for a retrospective observational study of the safety of metformin use in patients with chronic kidney disease, compared to other commonly used diabetes drugs. It will be conducted using retrospective data from the New York City CDRN, Medicare administrate files, and New York State Medicaid administrative files, which will be linked and then deidentified prior to analysis.
Interventions
- DRUG Metformin
- DRUG SGLT2 inhibitor
- DRUG Sulfonylurea
- DRUG DPP-4 inhibitor
- DRUG GLP1 receptor agonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,888 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2023-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03921242
The ClinicalTrials.gov registry entry for NCT03921242 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4,888 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.
NCT03921242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03921242 about?
NCT03921242 is a clinical study titled "Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease". This is a proposal for a retrospective observational study of the safety of metformin use in patients with chronic kidney disease, compared to other commonly used diabetes drugs. It will be conducted using retrospective data from the New York City CDRN, Medicare administrate files, and New York Stat...
What is the current status of trial NCT03921242?
This trial is currently completed. The enrollment target is 4,888 participants. The study started on 2019-08-01. Estimated completion is 2023-08-01.
What interventions are being tested in trial NCT03921242?
The interventions under investigation include: Metformin (DRUG), SGLT2 inhibitor (DRUG), Sulfonylurea (DRUG), DPP-4 inhibitor (DRUG), GLP1 receptor agonist (DRUG).
Who is sponsoring clinical trial NCT03921242?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.